Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 19.5% in February

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 9,900 shares, a decline of 19.5% from the February 13th total of 12,300 shares. Based on an average trading volume of 5,900 shares, the days-to-cover ratio is currently 1.7 days.

Clinuvel Pharmaceuticals Stock Up 1.5 %

Clinuvel Pharmaceuticals stock opened at $7.41 on Tuesday. The stock’s 50 day moving average is $7.40 and its 200 day moving average is $8.43. Clinuvel Pharmaceuticals has a one year low of $6.80 and a one year high of $11.40.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).